MX389169B - Compuestos y composiciones para inducir la condrogenesis. - Google Patents

Compuestos y composiciones para inducir la condrogenesis.

Info

Publication number
MX389169B
MX389169B MX2019014757A MX2019014757A MX389169B MX 389169 B MX389169 B MX 389169B MX 2019014757 A MX2019014757 A MX 2019014757A MX 2019014757 A MX2019014757 A MX 2019014757A MX 389169 B MX389169 B MX 389169B
Authority
MX
Mexico
Prior art keywords
compounds
compositions
inducing
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
MX2019014757A
Other languages
English (en)
Spanish (es)
Other versions
MX2019014757A (es
Inventor
Bao Nguyen
Ha- Soon Choi
Hank Michael James Petrassi
James Paul Lajiness
Jiqing Jiang
Zhicheng Wang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2019014757A publication Critical patent/MX2019014757A/es
Publication of MX389169B publication Critical patent/MX389169B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/14—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from hepatocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2019014757A 2017-06-09 2018-06-07 Compuestos y composiciones para inducir la condrogenesis. MX389169B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762517394P 2017-06-09 2017-06-09
PCT/IB2018/054123 WO2018225009A1 (en) 2017-06-09 2018-06-07 Compounds and compositions for inducing chondrogenesis

Publications (2)

Publication Number Publication Date
MX2019014757A MX2019014757A (es) 2020-02-12
MX389169B true MX389169B (es) 2025-03-20

Family

ID=62837959

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014757A MX389169B (es) 2017-06-09 2018-06-07 Compuestos y composiciones para inducir la condrogenesis.

Country Status (37)

Country Link
US (3) US11091499B2 (enExample)
EP (3) EP3634967A1 (enExample)
JP (2) JP7229945B2 (enExample)
KR (1) KR102656524B1 (enExample)
CN (1) CN110719913B (enExample)
AR (1) AR113227A1 (enExample)
AU (1) AU2018279306C1 (enExample)
BR (1) BR112019025866A2 (enExample)
CL (1) CL2019003564A1 (enExample)
CO (1) CO2019013706A2 (enExample)
CR (1) CR20190551A (enExample)
CU (1) CU24577B1 (enExample)
DK (1) DK3915994T3 (enExample)
DO (1) DOP2019000305A (enExample)
EA (1) EA201992858A1 (enExample)
EC (1) ECSP19086712A (enExample)
ES (1) ES2971319T3 (enExample)
FI (1) FI3915994T3 (enExample)
HR (1) HRP20240155T1 (enExample)
HU (1) HUE065194T2 (enExample)
IL (2) IL300755A (enExample)
JO (1) JOP20190282B1 (enExample)
LT (1) LT3915994T (enExample)
MA (2) MA50547A (enExample)
MX (1) MX389169B (enExample)
MY (1) MY198288A (enExample)
PE (1) PE20200403A1 (enExample)
PH (1) PH12019502764A1 (enExample)
PL (1) PL3915994T3 (enExample)
PT (1) PT3915994T (enExample)
RS (1) RS65161B1 (enExample)
SA (1) SA519410729B1 (enExample)
SI (1) SI3915994T1 (enExample)
TW (1) TWI782036B (enExample)
UY (1) UY37759A (enExample)
WO (1) WO2018225009A1 (enExample)
ZA (1) ZA201907358B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY37759A (es) * 2017-06-09 2019-01-31 Novartis Ag Compuestos y composiciones para inducir condrogénesis
ES2963508T3 (es) * 2018-12-06 2024-03-27 Novartis Ag Derivados de 5-hidroxi-7-oxabiciclo[2.2.1]heptano-2-carboxamida para inducir condrogénesis para el tratamiento del daño articular
WO2020115684A1 (en) * 2018-12-06 2020-06-11 Novartis Ag 6-hydroxy-8-oxatricyclo[3.2.1.02,4]octane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077864A (en) 1997-01-06 2000-06-20 Pfizer Inc. Cyclic sulfone derivatives
ECSP982358A (es) 1998-01-06 1998-12-22 Derivados ciclicos de sulfona
US6407250B1 (en) * 2000-09-14 2002-06-18 Allergan Sales, Inc. Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2a antagonists
US6369089B1 (en) 2000-09-14 2002-04-09 Allergan Sales, Inc. Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2α antagonists
CN1213050C (zh) 2000-11-23 2005-08-03 拜尔公司 氧杂双环[2.2.1]庚烷衍生物，其制备方法和作为农药的用途
US6653468B1 (en) 2002-07-31 2003-11-25 Isis Pharmaceuticals, Inc. Universal support media for synthesis of oligomeric compounds
JP2005068052A (ja) 2003-08-22 2005-03-17 Mitsui Chemicals Inc 新規なフラン誘導体及びその製造方法
WO2006038112A1 (en) 2004-10-01 2006-04-13 Warner-Lambert Company Llc Use of kinase inhibitors to promote neochondrogenesis
US7595327B2 (en) * 2005-03-21 2009-09-29 Wyeth Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase
US9233106B2 (en) 2006-07-12 2016-01-12 Cornell Research Foundation, Inc. Inhibition of beta-amyloid peptide aggregation
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
WO2010114997A1 (en) 2009-04-02 2010-10-07 Allergan, Inc. Prostaglandin e receptor antagonists
PE20160507A1 (es) 2009-07-14 2016-05-20 Scripps Research Inst Diferenciacion de celulas madre mesenquimales
CN101628951B (zh) 2009-08-12 2011-06-22 中国石油天然气股份有限公司 烯烃聚合用固体催化组分及其催化剂
EP2651405A2 (en) 2010-12-14 2013-10-23 Electrophoretics Limited Casein kinase 1 (ck1 ) inhibitors
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2012177856A2 (en) 2011-06-21 2012-12-27 Adispell, Inc. Cognition modification
WO2013007765A1 (en) * 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
EP2968330B1 (en) * 2013-03-15 2021-09-29 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
HRP20241236T1 (hr) * 2014-05-13 2024-12-06 Novartis Ag Spojevi i pripravci za induciranje hondrogeneze
JP2016204316A (ja) 2015-04-24 2016-12-08 日東電工株式会社 核酸固相合成用リンカー及び担体
UY37759A (es) 2017-06-09 2019-01-31 Novartis Ag Compuestos y composiciones para inducir condrogénesis

Also Published As

Publication number Publication date
EP4299123A2 (en) 2024-01-03
EP4299123A3 (en) 2024-04-03
TW201902900A (zh) 2019-01-16
JOP20190282B1 (ar) 2024-04-18
IL300755A (en) 2023-04-01
CN110719913A (zh) 2020-01-21
JP7432778B2 (ja) 2024-02-16
NZ759434A (en) 2024-01-26
CO2019013706A2 (es) 2020-04-01
RU2019144107A3 (enExample) 2021-07-30
PH12019502764A1 (en) 2020-07-13
AU2018279306A1 (en) 2019-12-05
US20210079010A1 (en) 2021-03-18
HRP20240155T1 (hr) 2024-04-12
CN110719913B (zh) 2022-10-28
PE20200403A1 (es) 2020-02-26
CU24577B1 (es) 2022-02-04
EP3634967A1 (en) 2020-04-15
MA50547A (fr) 2020-09-16
BR112019025866A2 (pt) 2020-07-14
CR20190551A (es) 2020-01-28
KR102656524B1 (ko) 2024-04-12
FI3915994T3 (fi) 2024-02-14
MA57022B1 (fr) 2024-02-29
IL271154B2 (en) 2023-07-01
JP2023062064A (ja) 2023-05-02
SA519410729B1 (ar) 2022-07-03
PT3915994T (pt) 2024-02-15
JP7229945B2 (ja) 2023-02-28
JOP20190282A1 (ar) 2019-12-05
DOP2019000305A (es) 2019-01-15
TWI782036B (zh) 2022-11-01
ES2971319T3 (es) 2024-06-04
US20230365580A1 (en) 2023-11-16
IL271154B1 (en) 2023-03-01
WO2018225009A1 (en) 2018-12-13
PL3915994T3 (pl) 2024-05-20
EP3915994A1 (en) 2021-12-01
KR20200013046A (ko) 2020-02-05
US20210347784A1 (en) 2021-11-11
CU20190098A7 (es) 2020-10-20
US12209096B2 (en) 2025-01-28
EP3915994B9 (en) 2024-02-28
AU2018279306C1 (en) 2021-01-14
MX2019014757A (es) 2020-02-12
AU2018279306B2 (en) 2020-07-09
AR113227A1 (es) 2020-02-19
DK3915994T3 (da) 2024-02-19
MY198288A (en) 2023-08-21
CL2019003564A1 (es) 2020-06-19
ZA201907358B (en) 2022-04-28
US11753416B2 (en) 2023-09-12
UY37759A (es) 2019-01-31
IL271154A (en) 2020-01-30
EA201992858A1 (ru) 2020-04-02
EP3915994B1 (en) 2023-11-22
CA3063985A1 (en) 2018-12-13
RU2019144107A (ru) 2021-07-09
RS65161B1 (sr) 2024-02-29
JP2020522550A (ja) 2020-07-30
HUE065194T2 (hu) 2024-05-28
SI3915994T1 (sl) 2024-03-29
LT3915994T (lt) 2024-02-26
US11091499B2 (en) 2021-08-17
ECSP19086712A (es) 2019-12-27

Similar Documents

Publication Publication Date Title
PH12016502005A1 (en) Compounds and compositions for inducing chondrogenesis
CL2021000972A1 (es) Inhibidores de la proteína tirosina fosfatasa
DOP2021000077A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
PY1932509A (es) Inhibidores de cinasa dependientes de ciclina
NZ754207A (en) 3-substituted propionic acids as alpha v integrin inhibitors
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
EA201691428A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
MX2020002924A (es) Lactamas fusionadas de arilo y heteroarilo.
WO2017132432A8 (en) Benzimidazole derivatives as modulators of ror-gamma
EA033497B1 (ru) 1-(тиофенил или фенил)сульфонил-(пирролидин)-2-карбоксамидные производные и их применение в качестве антагонистов trpa1
EA201991884A3 (ru) Ингибиторы g12c kras
MX343160B (es) Dicetopiperazinas para uso en inhibir hiperpermeabilidad vascular.
JOP20220085A1 (ar) مركبات أريل ميثيلين حلقية غير متجانسة على هيئة حاصرات قناة بوتاسيوم Kv1.3 بجين شاكر
PH12019502764A1 (en) Compounds and compositions for inducing chondrogenesis
WO2017177004A8 (en) Tertiary amides and method of use
WO2018209363A3 (en) PROPIONIC ACID DERIVATIVES AND ASSOCIATED METHODS OF USE
TN2016000459A1 (en) Cycloalkyl-linked diheterocycle derivatives.
MX2017003458A (es) Indazol ureas y metodo de uso.
WO2016112304A8 (en) Furoquinolinediones as inhibitors of tdp2
AR116080A1 (es) Derivados de 1-imidazotiadiazol-2h-pirrol-5-ona
PH12022550774A1 (en) Quinolone carboxylic acid derivatives
CR20250037A (es) Inhibidores de cinasa dependientes de ciclina (divisional 2020-0503)